VISTEL-40 (Telmisartan Tablets IP 40 mg)
VISTEL-40, manufactured by Solvista Healthcare, is a prescription medication primarily indicated for the management of hypertension (high blood pressure) and the reduction of cardiovascular risk. As a formulation of Telmisartan Tablets IP 40 mg, it belongs to a critical class of drugs known as Angiotensin II Receptor Blockers (ARBs).
Composition and Mechanism of Action
The active pharmaceutical ingredient in VISTEL-40 is Telmisartan (40 mg). In the human body, a hormone called angiotensin II causes blood vessels to constrict, which increases blood pressure and puts additional strain on the heart. Telmisartan works by selectively blocking the binding of angiotensin II to the $AT_1$ receptors in many tissues, such as vascular smooth muscle and the adrenal gland. By preventing this binding, VISTEL-40 promotes vasodilation (widening of the blood vessels) and reduces the secretion of aldosterone. The result is a significant decrease in systemic blood pressure and improved blood flow.
Key Therapeutic Benefits
According to the clinical profile of the product, VISTEL-40 offers several distinct advantages for patients struggling with chronic hypertension:
- Long-Lasting 24-Hour BP Control: One of the most significant features of Telmisartan is its long terminal elimination half-life (approximately 24 hours). This ensures that blood pressure remains stable throughout the day and night, specifically providing protection during the early morning hours when the risk of stroke and heart attack is statistically highest.
- Effective ARB Therapy: As an ARB, it provides a robust alternative to ACE inhibitors. It is often preferred because it does not interfere with the breakdown of bradykinin, significantly reducing the likelihood of the “dry cough” often associated with other blood pressure medications.
- Cardiovascular Risk Reduction: Beyond simply lowering numbers on a monitor, VISTEL-40 is indicated for the reduction of cardiovascular morbidity in patients who are at high risk of manifest cardiovascular disease, such as those with a history of coronary artery disease or stroke.
- Once-Daily Dosing: The pharmacokinetic profile allows for a convenient “once-a-day” regimen. This simplicity is vital for patient compliance, ensuring that users are more likely to stick to their treatment plan over the long term.
- Well-Tolerated Profile: Clinical studies typically show that Telmisartan has a side-effect profile similar to a placebo, making it a reliable and well-tolerated therapy for a broad demographic of adult patients.
Packaging and Presentation
Solvista Healthcare presents VISTEL-40 in a professional blister pack format. The standard packaging shown is 10 x 15 Tablets, totaling 150 tablets per box. This bulk packaging is particularly useful for chronic conditions where long-term, uninterrupted therapy is required. Each tablet is precisely dosed at 40 mg, which is the standard starting dose for most hypertensive adults.
